REDWOOD CITY, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that the company will present at two upcoming investor conferences in September 2015.
- Kristine M. Ball, senior vice president and chief financial officer, will present at the 22nd Annual NewsMakers in the Biotech Industry Conference, September 10, 2015, at 11:30 a.m. ET.
- John A. Orwin, president and chief executive officer, will provide an update at the Morgan Stanley Global Healthcare Conference 2015, September 16, 2015, at 3:40 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company's lead product candidate is Patiromer for Oral Suspension for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood. A two-part pivotal Phase 3 trial of Patiromer for Oral Suspension has been completed and the primary and secondary endpoints were met. A New Drug Application for Patiromer for Oral Suspension for the treatment of hyperkalemia was accepted by the U.S. Food and Drug Administration and is currently under review. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.